HomeStartups Can-Fite BioPharma lifecycle

Claimed by owner Last Update May 18, 2026 Suggest Edits Claim Profile

Claimed by owner

Can-Fite BioPharma

Targeted Drugs for Cancer and Inflammatory Diseases

PUBLIC on TASE on Sep 2005

PUBLIC on NYSE on Jul 2025

Can-Fite BioPharma

Can-Fite BioPharma Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

#Product Stage

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

#Investment

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

#Product Stage

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

#Product Stage

Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy

#Product Stage #Partners

Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson

#Product Stage

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson

#Product Stage

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction

#Product Stage

Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Sector Update: Health Care Stocks Lower in Friday Afternoon Trading

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Can-Fite Provides Update on Clinical and Financial Status

#Product Stage #PIPE/PO

Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

#Product Stage #Partners

Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference

#Product Stage #Partners

Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

#Product Stage

Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson

#Product Stage #FDA approved/pending approval

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Clues on Fed's Interest Rate Cut

Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson

#Product Stage

Can-Fite Reports H1 2025 Financial Results and Clinical Update

#Product Stage

Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone

#Product Stage

Can-Fite Announces Up To $15.0 Million Public Offering

#PIPE/PO

Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia

#Product Stage #FDA approved/pending approval

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston

#Product Stage #Partners

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

#Investment #Product Stage #Partners

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

#Product Stage #FDA approved/pending approval

Can-Fite Reports 2024 Financial Results and Clinical Update

#Product Stage #FDA approved/pending approval

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

#Product Stage #Partners

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

#PIPE/PO

bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

#Product Stage #Customers

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

#Product Stage

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

#Product Stage #Partners

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

#Product Stage #Partners

Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

#FDA approved/pending approval

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

#Product Stage #FDA approved/pending approval

Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

#Product Stage

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

#Product Stage #Investment

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

#Product Stage #Partners

Can-Fite BioPharma secures US patent for Namodenoson

#Product Stage

US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

#Product Stage

CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson

Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now

8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug

#Customers

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

#Customers #Partners

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Secures Australian Patent for Obesity Drug

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

#Partners

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29

Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis

#Partners

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

#Customers

Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?

#Partners

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

#Investment #Partners #Customers

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

#Customers, Partners, Expand

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

#Investment

Can-Fite Provides Namodenoson Patent Update

#Investment #Expand

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8

#Investment

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

#Investment #Expand

Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

#Investment, Expand

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial

#Investment #Expand

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

#Customers, Partners

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV

#Customers

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

#Investment

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson

#Investment

Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds

#Investment

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

#Investment

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Best Momentum Stocks to Buy for October 27th

#Investment

New Strong Buy Stocks for October 27th

#Investment

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

#Management Changes

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

#Customers #Partners

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

#Partners

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

#Customers

Presenting on the Emerging Growth Conference on August 9 & 10 Register Now

#Partners

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

Presenting on the Emerging Growth Conference on July 12 & 13 Register Now

#Customers, Partners

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

#Investment, Expand

Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer

#Customers

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

#Investment, Expand

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

#Partners, Expand

All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy

#Investment

Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization

Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

#Investment, Expand

Can-Fite Reports 2022 Financial Results & Provides Clinical Update

Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo

Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow

#Investment, Expand

Can-Fite Announces ADS Ratio Change

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer

#Investment

Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update

Can-Fite's Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress

Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

#Partners #Customers

Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis

Can-Fite's CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

Can-Fite's Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv

Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

#Investment #Expand

Can-Fite Announces $10.0 Million Registered Direct Offering

Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment;Top Line Results Expected Q4 2021

Can-Fite Expands its Phase II COVID-19 Study to Europe

Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates

Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model

#Investment

Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson

Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

#Investment, Expand

Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal-Cancers

Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs

Can-Fite Reports on Progress With Its Namodenoson NASH Program

Can-Fite's Namodenoson Abstract Selected as 'Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD)

Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis

FDA Clears Can-Fite to Commence Phase II COVID-19 Study

Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

#Investment, Expand

Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Can-Fite Announces $8.0 Million Registered Direct Offering

Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.

Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer

Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office

Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis

Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms

Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET

#Investment

Can-Fite Gets Approval For COVID-19 Clinical Trial For Piclidenoson In Israel

#Customers

Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020

https://seekingalpha.com/pr/17812127-can-fite-to-participate-in-digital-bio-europe-spring-partnering-conference-looks-to-partner

Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson

Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD

Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson

Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications

Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea;Results of its NASH Phase II Study are Expected this Quarter

Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis

Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects

Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial

https://www.marketwatch.com/press-release/can-fite-granted-patents-for-its-sexual-dysfunction-drug-2019-11-19

Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market

Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients

U.S. FDA Agreed with Can-Fite's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer

Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report

#Management Changes

Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™

Capital Point's hostile bid for Can-Fite ends in compromise

#Partners #Investment

Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine

Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel

Can-Fite BioPharma Signs South Korean Distribution Agreement for Psoriasis Treatment Drug

#Partners

Findings from Can-Fite's Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session

Can-Fite's Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

#Investment

Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement

#Partners

Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting BioSpace

#Investment

Can-Fite BioPharma to Raise $3.2 Million in Direct Offering

#Investment

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

Can-Fite fights hostile takeover

#Partners

Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert

#Management Changes #Expand

https://ir.canfite.com/press-releases/detail/824/drugs-with-mechanism-of-action-utilized-by-namodenoson-are-recommended-by-leading-u-s-researchers-to-be-developed-to-combat-liver-cancer

Can-Fite BioPharma Announces $5 Million Registered Direct Offering

#Investment

Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea

#Partners #Investment

Can-Fite rebounds on revised psoriasis trial analysis

#Customers

Can-Fite jumps on positive rheumatoid arthritis treatment results

#Customers

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

9/1994

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

Can-Fite BioPharma Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

News Over Time

News Articles